a month ago
ABBV
AnalystsCarter GouldCarter Gould's Stock Forecasts
AnalystsCarter Gould
Analyst Ranking
Top 21%
#956 out of 4565 analysts
Average Return
+3.41%
Win Rate
51%46 out of 90
Risk vs Reward
Poor
Good
Carter Gould's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Reata Pharmaceuticals IncRETA | +334.02% | $38.27 | $166.10 | 2022-11-09 - 2023-08-01 | Strong Buy |
Reata Pharmaceuticals IncRETA | +88.73% | $88.01 | $166.10 | 2023-05-11 - 2023-08-01 | Strong Buy |
Arcellx IncACLX | +83.59% | $28.52 | $52.36 | 2022-12-12 - 2023-12-11 | Strong Buy |
Eli Lilly & CoLLY | +78.62% | $405.81 | $724.87 | 2023-05-01 - 2024-04-25 | Strong Buy |
Reata Pharmaceuticals IncRETA | +78.28% | $93.17 | $166.10 | 2023-03-01 - 2023-08-01 | Strong Buy |
Carter Gould Analyst Color
Get additional color on Carter Gould's coverage of popular stocks
3 months ago
ABBV
3 months ago
REGN
3 months ago
NBIX
3 months ago
LLY
3 months ago
ABBV
4 months ago
PFE
6 months ago
PFE
6 months ago
ABBV
9 months ago
LLY
10 months ago
PFE
a year ago
PFE
a year ago
LLY
a year ago
PFE
a year ago
PFE
a year ago
PFE
a year ago
LLY
2 years ago
PFE
2 years ago
ABBV
2 years ago
ABBV
2 years ago
PFE
Carter Gould's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biogen IncBIIB | 19 | Hold | $200.00 | -1.22% | Maintains | a day ago |
Skillsoft CorpSKIL | 5 | Strong Buy | $20.00 | +194.12% | Maintains | 10 days ago |
Abbvie IncABBV | 10 | Strong Buy | $195.00 | +16.56% | Maintains | a month ago |
Arcellx IncACLX | 4 | Strong Buy | $73.00 | +42.08% | Maintains | 2 months ago |
Gilead Sciences IncGILD | 10 | Hold | $80.00 | +22.57% | Maintains | 2 months ago |
Merck & Co IncMRK | 8 | Strong Buy | $145.00 | +10.92% | Maintains | 3 months ago |
Regeneron Pharmaceuticals IncREGN | 10 | Strong Buy | $1,020.00 | +14.52% | Maintains | 3 months ago |
Neurocrine Biosciences IncNBIX | 7 | Strong Buy | $150.00 | +8.89% | Maintains | 3 months ago |
Eli Lilly & CoLLY | 8 | Strong Buy | $680.00 | -6.19% | Maintains | 3 months ago |
Allakos IncALLK | 4 | Strong Sell | $1.00 | -0.99% | Maintains | 3 months ago |
Pfizer IncPFE | 11 | Hold | $28.00 | +10.85% | Maintains | 4 months ago |
Bristol Myers Squibb CoBMY | 9 | Hold | $51.00 | +14.09% | Maintains | 6 months ago |
Travere Therapeutics IncTVTX | 3 | Strong Buy | $12.00 | +122.63% | Maintains | 7 months ago |
Reata Pharmaceuticals IncRETA | 7 | Hold | $172.00 | -0.21% | Downgrades | 9 months ago |
Amgen IncAMGN | 12 | Strong Sell | $210.00 | -22.04% | Maintains | 10 months ago |
Alector IncALEC | 2 | Strong Buy | $12.00 | +149.48% | Maintains | a year ago |
Gossamer Bio IncGOSS | 5 | Hold | $1.50 | N/A | Maintains | a year ago |
Vor Biopharma IncVOR | 2 | Strong Buy | $15.00 | N/A | Maintains | a year ago |
Molecular Templates IncMTEM | 3 | Strong Buy | $15.00 | N/A | Maintains | a year ago |
Applied Therapeutics IncAPLT | 4 | Hold | $2.25 | N/A | Maintains | 2 years ago |
Paycom Software IncPAYC | 1 | Hold | $380.00 | N/A | Maintains | 2 years ago |
Acceleron Pharma IncXLRN | 3 | Hold | $180.00 | N/A | Downgrades | 3 years ago |
Cytokinetics IncCYTK | 1 | Strong Buy | $40.00 | N/A | Maintains | 3 years ago |
Celgene CorpCELG | 3 | Hold | N/A | N/A | Downgrades | 5 years ago |
Incyte CorpINCY | 3 | Hold | $82.00 | N/A | Downgrades | 5 years ago |
Vertex Pharmaceuticals IncVRTX | 1 | Hold | $188.00 | N/A | Maintains | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.